Person: TOPTAŞ, TAYFUR
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
TOPTAŞ
First Name
TAYFUR
Name
40 results
Search Results
Now showing 1 - 10 of 40
Publication Metadata only Precursor B cell lymphoblastic lymphoma presenting as a solitary bone tumor: a case report and review of the literature(SPRINGER TOKYO, 2010) TOPTAŞ, TAYFUR; Kaygusuz, Isik; Toptas, Tayfur; Guven, Aslihan; Firatli-Tuglular, Tulin; Tecimer, Tulay; Bayik, MahmutPrecursor B cell lymphoblastic lymphoma (B-LBL) is quite uncommon and it usually manifests as an extranodal disease. Although B-LBL may present with bone involvement, it is a very rare manifestation of B-LBL as a primary solitary bone tumor. Here, we report a case of precursor B-LBL presenting with solitary bone tumor and a review of a total of seven adult patients reported previously in the literature. We described demographic and clinical characteristics of these patients with unique presentation and discussed treatment options. Unlike previous reports except one case, our patient underwent allogeneic stem cell transplantation (allo-SCT) due to refractory disease. She is alive without evidence of disease by the post-transplant 12th month. B-LBL has an aggressive clinical course in adult patients and allo-SCT may be the best treatment option.Publication Open Access Newly diagnosed breast cancer in a patient receiving imatinib mesylate(2014) YUMUK, PERRAN FULDEN; Toptas, Tayfur; Yumuk, Fulden; Firatli-Tuglular, Tulin; Bayik, Mahmut; Kaygusuz-Atagunduz, IsikPublication Open Access Miliary Tuberculosis Induced Acute Liver Failure(HINDAWI LTD, 2015) BİLGİN, HÜSEYİN; Toptas, Tayfur; Ilhan, Birkan; Bilgin, Huseyin; Dincses, Elif; Ozdogan, Osman; Kaygusuz-Atagunduz, Isik; Odabasi, Zekaver; Korten, Volkan; Firatli-Tuglular, TulinHepatobiliary tuberculosis is uncommon even in endemic countries. It is associated with a high mortality and is even diagnosed early in the disease course. Acute liver failure (ALF) caused by tuberculosis bacilli has been reported in only a few reports. All previous cases have been diagnosed by postmortem examination. Time to antituberculosis treatment is very critical. In case of suggestive findings on clinical and radiologic examination, antituberculosis treatment should be initiated immediately. Drug use can be a challenge in patients with ALF. However, as long as the other possible causes of ALF can be excluded and hepatotoxic drugs were avoided during the early course of treatment, such a highly fatal presentation of tuberculosis can be treated safely. Here, we report a case of acute liver failure as a presentation of miliary tuberculosis. He was treated successfully with antituberculosis treatment.Publication Open Access Predictive immune markers for disease progression in multiple myeloma and monoclonal gammopathy of undetermined significance(2022-12-01) TOPTAŞ, TAYFUR; TÜRKÖZ, HÜSEYİN KEMAL; İşgör İ. Ş., TOPTAŞ T., TÜRKÖZ H. K.©Copyright 2022 by Turkish Society of Hematology | Turkish Journal of Hematology, Published by Galenos Publishing HouseObjective: Multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS), the precursor of MM, are plasma cell neoplasms. The evolution of the treatment of MM in recent years has dramatically improved the outcome for these patients. Currently, multidisciplinary studies are being conducted to elucidate the etiopathogenesis of the disease and develop specific treatment agents and prognostic markers. The present study investigates the relationships between immunoexpression of CD138, Pan-Ras, CCL-3, DKK-1, and MUM-1 and disease progression in cases of MM and MGUS. Materials and Methods: Immunohistochemical staining for CD138, Pan-Ras, CCL-3, DKK-1, and MUM-1 were performed on bone marrow biopsy samples from 94 MM and 20 MGUS patients diagnosed between 2011 and 2018. Immunohistochemical results were examined semiquantitatively, and the associations between the immunohistochemical, clinical, and biochemical markers utilized for MM and MGUS patient staging were analyzed. Results: Pan-Ras, DKK-1, and MUM-1 staining results were significantly higher in MM compared to MGUS (p=0.005, 0.001, and 0.001, respectively). The mean CCL-3 expression in patients with MGUS was 23.15%, while it was 18.68% in cases of MM (p=0.413). CCL-3 expression was significantly higher in high-risk MGUS cases compared to other risk groups according to the Mayo Clinic Risk Stratification for MGUS. According to the International Staging System and the Revised International Staging System, CD138 expression was higher among stage II and stage III patients than stage I patients. Conclusion: Differences in Pan-Ras, MUM-1, DKK-1, and CCL-3 expressions between MM and MGUS suggest that these molecules may play a role in the progression of MGUS to MM. CCL-3, an immunohistochemical marker, may be predictive of MGUS progression, while CD138 is associated with more advanced stages of MM. Amaç: Multipl myelom (MM) ve MM’nin prekürsörü olan önemi belirsiz monoklonal gamopati (MGUS), plazma hücreli neoplazilerdir. Güncel çalışmalarda bu hastalıkların etiyopatogenezini aydınlatmak, spesifik tedavi ajanları ve prognostik belirteçler geliştirmek için multidisipliner çalışmalar yürütülmektedir. Çalışmamızda MM ve MGUS’lerde CD138, Pan-Ras, CCL-3, DKK-1 ve MUM1 immünoekspresyonun hastalık evreleriyle olan ilişkisini araştırmayı hedefledik. Gereç ve Yöntemler: 2011-2018 yılları arasında tanı alan 94 MM ve 20 MGUS olgusuna ait kemik iliği biyopsilerine, CD138, Pan-Ras, CCL-3, DKK-1, MUM-1 immünohistokimyasal (İHK) boyaması yapıldı. İHK sonuçları semi kantitatif olarak değerlendirildi ve MM ve MGUS olgularının hastalık evreleriyle olan ilişkileri değerlendirildi. Bulgular: Pan-Ras, DKK-1 ve MUM-1 immünoekspresyonu, MM’li olgularda MGUS’li olgulara göre anlamlı olarak daha yüksek saptandı (p=0,005, 0,001, ve 0,001, sırasıyla). MGUS olgularında ortalama CCL-3 immünoekspresyonu %23,15 iken, MM olgularında %18,68 idi (p=0,413). MGUS olgularında Mayo Klinik risk sınıflandırması (MCRS) modeline göre, yüksek riskli MGUS olgularında diğer risk gruplarına kıyasla CCL-3 ekspresyonu önemli ölçüde artmış olarak saptandı. CD138 ekspresyonu, ISS ve R-ISS sınıflama sistemlerine göre, evre 2 ve evre 3 hastalarda evre 1 hastalara göre artmış olarak tespit edildi. Sonuç: MM ve MGUS olgularında Pan-Ras, MUM-1, DKK-1 ve CCL-3 ekspresyonlarındaki farklılıklar, bu belirteçlerin MGUS-MM progresyonunda önemli roller üstlendiğini göstermektedir. Kemik iliği biyopsilerinde, kolay ve pratik bir şekilde, CCL-3 immün belirteci MGUS progresyonunda prediktif; CD138 ise MM olgularında ileri evre tayininde kullanılabilir.Publication Open Access Severe Acute Hemolytic Transfusion Reaction Treated with Ruxolitinib and Plasma Exchange(KARGER, 2021) TOPTAŞ, TAYFUR; Deveci, Burak; Saba, Rabin; Altunay, Husnu; Toptas, Tayfur; Kublashvilli, George; Karadogan, IhsanIntroduction: Acute hemolytic transfusion reaction is a rare but extremely mortal condition. Even small quantities of ABO-incompatible erythrocytes, as much as 50 mL, can lead to fatality. Since there is no successful standard therapy, preventive measures are very important. In this case report, we presented a 29-year-old woman who was transfused with 2 units of AB Rh-positive instead of 0 Rh-positive red blood cells following a cesarean section. As far as we know, this is the first patient in the literature for whom ruxolitinib was used as a part of therapy. Case Report: The patient was referred to our center 22 h after the ABO-mismatched transfusion. On admission, she had severe hemolysis, acute renal failure, and disseminated intravascular coagulation. Massive plasma exchange, hemodialysis, and pulse steroid therapy were commenced. The patient was refractory to first-line therapies. She was intubated on day 2 due to hypoxia, respiratory failure and changes in consciousness. Ruxolitinib, 2 x 10 mg/day, was started on day 3. The patient's clinical status improved on day 6. Ruxolitinib was withdrawn on day 15, and the patient was discharged without any complications or sequels on day 26. Conclusion: Ruxolitinib may be life-saving in patients with ABO-incompatible transfusion reaction which follows a severe and catastrophic course. (c) 2021 S. Karger AG, BaselPublication Open Access Efficacy of F-18-2-fluoro-2-deoxy-D-glucose Positron Emission Tomography/Computerized Tomography for Bone Marrow Infiltration Assessment in the Initial Staging of Lymphoma(GALENOS YAYINCILIK, 2017-06-07) TOPTAŞ, TAYFUR; Oner, Ali Ozan; Budak, Evrim Surer; Aydin, Funda; Salim, Ozan; Yucel, Orhan Kemal; Akkaya, Bahar; Toptas, Tayfur; Boz, Adil; Yildiz, Akin; Gungor, Firat; Undar, LeventObjective: Currently F-18-2-fluoro-2-deoxy-D-glucose (F-18-FDG) positron emission tomography/computerized tomography (PET/CT) is being successfully used for staging and follow-up of Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL). Various studies have demonstrated that PET/CT effectively detects bone marrow involvement (BMI) and is concordant with bone marrow biopsy (BMB) findings, thus it is deemed as a complementary method. This study was aimed to evaluate-F-18-FDG-PET/CT efficiency for detection of BMI in HL and NHL. Methods: The study included 172 lymphoma cases who were admitted to Akdeniz University Medical School Department of Nuclear Medicine for initial staging with PET/CT. Visual and semiquantitative assessments were performed for PET/CT scan findings of the cases. The maximum standard uptake (SUVmax) value was the quantitative parameter used for F-18-FDG-PET scan. In visual assessment, bone marrow metabolic activity that is greater than the liver was considered as pathologic. For semiquantitative assessment, regions of interest were drawn for SUVmax estimation, which included iliac crest in cases with diffusely increased metabolic activity and the highest activity area in cases with focal involvement. BMB was considered as the reference test. Results: On visual assessment of all the cases, PET/CT was found to yield 31% sensitivity and 85% specificity rate for detection of BMI. On visual assessment of HL cases, sensitivity rate was determined as 80%, and specificity as 78%, while in NHL cases the corresponding values were 24% and 90%, respectively. On semiquantitative assessment of HL cases, considering SUVmax=4, sensitivity was found as 80% and specificity as 68%. In NHL patients, considering SUVmax=3.2, sensitivity rate was detected as 65% and specificity as 58%. Conclusion: In this study, a moderately high concordance was observed between PET/CT and BMB findings. PET/CT appears to be a significant method for detecting BMI. Although PET/CT is not a substitute for BMB, we suggest it can be used as a guide to biopsy site and a complementary imaging technique for BMB.Publication Metadata only Hematoloji dergilerinde bilimsel yayıncılık: Bilim-ölçüsel ve ekonomik bir değerlendirme(2020-10-31) TAZEGÜL, GÖKHAN; TOPTAŞ, TAYFUR; TAZEGÜL G., ATAŞ Ü., ULAŞ T., TOPTAŞ T., SALİM O.Publication Open Access Investigation of typhlitis in bone marrow transplant patients in a stem cell transplant unit(2022-08-01) TOPTAŞ, TAYFUR; Deveci B., Kublashvili G., Yilmaz S., Ozcan B., Korkmaz H. F. , Gursoy O., TOPTAŞ T., Dosemeci L., Saba R.Typhlitis is a special type of enterocolitis that specifically develops in immunosuppressive patients with hematological malignancies. Typhlitis is a common consideration after bone marrow transplantation due to high-dose chemotherapy that is used in conditioning regimens those contain high-dose cytotoxic chemotherapeutic agents. Although there are several studies about typhlitis during chemotherapy or in leukemia patients, there is not enough data evaluating its relationship between stem cell transplant in adults. Therefore, the current study aimed to analyze the possible causes that may lead to the development of typhlitis in hematopoietic stem cell recipient patients. This retrospective study included 210 adult patients who underwent bone marrow transplantation between January 2017 and December 2019. Pediatric patients (patients younger than 18 years of age) were excluded. Patients\" data were evaluated to determine their effects on typhlitis and the mortality risk of the patients with typhlitis. The analysis of the variables was performed using the IBM SPSS Statistics for Windows version 26 (IBM Corp., Armonk, NY).Variables were analyzed at a 95% confidence level and a P value <0.05 was considered significant. Typhlitis developed in 23 (10.9%) transplant patients. Male sex, length of hospital stay, presence of febrile neutropenia, antibiotic and antifungal use, need for switching antibiotics, duration of neutropenia, diarrhea and antibiotic use in days were risk factors for development of typhlitis. It was observed that 100-days mortality was higher in typhlitis group reaching to a statistical significance (P < .05). In multiple logistic regression analysis, presence of mucositis and additional source of infection were determined as independent risk factors for the development of typhlitis in bone marrow transplant patients. This study provides valuable information for bone marrow transplant patients through an analysis of risk factors for the development of typhlitis. According to our results, mucositis and additional bacterial infections were found as risk factors for typhlitis therefore it would be beneficial for clinicians to consider these factors in patient follow-up. However, due to the retrospective nature of our study, prospective studies are needed to investigate risk factors and optimum treatment methods for typhlitis.Publication Metadata only Publishing in hematology journals: A Scientometric and economic evaluation(2020-12-01) TOPTAŞ, TAYFUR; Tazegul G., Atas U., Ulas T., TOPTAŞ T., SALİM O.Introduction: Herein, we aimed to compare the scientometric data of hematology journals, and compare the publication models, especially the scientometric data of journals with all-open access (OA) and hybrid-OA publication models.Publication Metadata only Akut lenfositik lösemi tanili olgularda fish analizi ile saptanan kromozomal yeniden düzenlenmelerin retrospektif incelenmesi(2021-11-28) GEÇKİNLİ, BİLGEN BİLGE; TOPTAŞ, TAYFUR; TRUE, ÖMER; ATA, PINAR; ALAVANDA C., GEÇKİNLİ B. B., Başer Z. M., Dirimtekin E., Demir Ş., POLAT H., ARSLAN ATEŞ E., TOPTAŞ T., DOĞRU Ö., ATA P., et al.